Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.10 is 88% above its 5-year average of -0.87, near the high end of its 5-year range (-2.14–0.00).
45.43% above its 12-month average of -0.18.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.18.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 30 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T21:04:06.323Z. Historical observations retain their original dates. Historical series through 2026-08-06.
EARNINGS PER SHARE (EPS)
-0.10
EARNINGS PER SHARE (EPS) AVG TTM
-0.18
EARNINGS PER SHARE (EPS) AVG 3Y
-0.38
EARNINGS PER SHARE (EPS) AVG 5Y
-0.87
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+45.43%
CURRENT VS 3Y AVG
+73.62%
CURRENT VS 5Y AVG
+88.48%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Xeris Biopharma Holdings, Inc.
Market Cap
$1.74B
Earnings Per Share (EPS)
-0.10
TTM Avg
-0.18
3Y Avg
-0.38
5Y Avg
-0.87
Market Cap
$1.74B
Earnings Per Share (EPS)
-0.80
TTM Avg
-0.89
3Y Avg
-1.03
5Y Avg
-0.96
Market Cap
$1.74B
Earnings Per Share (EPS)
0.19
TTM Avg
-0.34
3Y Avg
-0.57
5Y Avg
-0.59
Market Cap
$1.74B
Earnings Per Share (EPS)
-1.30
TTM Avg
-1.39
3Y Avg
-1.40
5Y Avg
-0.99
Market Cap
$1.73B
Earnings Per Share (EPS)
-3.36
TTM Avg
-4.53
3Y Avg
-5.16
5Y Avg
-4.47
Market Cap
$1.75B
Earnings Per Share (EPS)
-0.69
TTM Avg
-0.97
3Y Avg
-0.66
5Y Avg
-1.16
Market Cap
$1.71B
Earnings Per Share (EPS)
-1.09
TTM Avg
-1.14
3Y Avg
-1.75
5Y Avg
-1.62
Market Cap
$1.77B
Earnings Per Share (EPS)
N/A
TTM Avg
-3.33
3Y Avg
-3.33
5Y Avg
-3.33
Market Cap
$1.71B
Earnings Per Share (EPS)
-2.74
TTM Avg
-3.74
3Y Avg
-3.13
5Y Avg
-1.84
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | $1.74B | -0.10 | -0.18 | -0.38 | -0.87 |
| Absci Corporation (ABSI)vs › | $1.74B | -0.80 | -0.89 | -1.03 | -0.96 |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.74B | 0.19 | -0.34 | -0.57 | -0.59 |
| Novocure Ltd (NVCR)vs › | $1.74B | -1.30 | -1.39 | -1.40 | -0.99 |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.73B | -3.36 | -4.53 | -5.16 | -4.47 |
| Surgery Partners, Inc. (SGRY)vs › | $1.75B | -0.69 | -0.97 | -0.66 | -1.16 |
| Personalis, Inc. (PSNL)vs › | $1.71B | -1.09 | -1.14 | -1.75 | -1.62 |
| Generate Biomedicines, Inc. (GENB)vs › | $1.77B | N/A | -3.33 | -3.33 | -3.33 |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | -2.74 | -3.74 | -3.13 | -1.84 |
| Zenas BioPharma, Inc. (ZBIO)vs › | $1.70B | -9.62 | -6.10 | -4.07 | -4.07 |
Trailing EPS (TTM)
$-0.10
Forward EPS (Est.)
$-0.04
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 0.00 |
| 2024-12-31 | -0.37 |
| 2023-12-31 | -0.45 |
| 2022-12-31 | -0.70 |
| 2021-12-31 | -1.55 |
| 2020-12-31 | -2.14 |
| 2018-12-31 | -4.99 |
| 2017-12-31 | -13.09 |
| 2016-12-31 | -7.17 |
